TrialJournal of neurology2017

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.

Caryl J Schwartzbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.